Last mentioned: Feb 26, 2026
Schrödinger and GoodRx reported full-year 2025 results, demonstrating the growing financial impact of AI-driven computational platforms in drug discovery and healthcare. These reports, alongside Churchill Downs' record performance, highlight a broader trend of data-centric companies leveraging machine learning to optimize specialized market verticals.
Churchill Downs, GoodRx, and Schrödinger released their 2025 fourth-quarter and full-year financial results, highlighting a year of strategic expansion in gaming, healthcare technology, and AI-driven drug discovery. The reports reflect a broader market trend of resilient consumer spending in entertainment and the increasing integration of software-as-a-service (SaaS) models in specialized industries.
GoodRx and Schrödinger released their full-year 2025 financial results, highlighting a critical period of transition for digital health and computational drug discovery. While GoodRx focused on stabilizing its prescription marketplace margins, Schrödinger demonstrated the growing scalability of its AI-driven software platform alongside its internal clinical pipeline.
GoodRx reported Q4 2025 sales that exceeded market expectations, yet shares fell nearly 12% as investors weighed future guidance and margin pressures. Meanwhile, Schrödinger is pivoting toward a hosted platform model, targeting 10-15% growth in annual contract value for its computational drug discovery suite.